Skip to main content
Health Podcast Library

A Discussion About the ADHERE Study: Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod in Patients With CIDP

Episode Description

In this AANEM podcast, Dr. Stino interviews Dr. Allen on the groundbreaking ADHERE study, published in Lancet Neurology in 2024, which investigated efgartigimod for treating chronic inflammatory demyelinating polyneuropathy (CIDP). As the largest CIDP trial to date with 322 patients across 146 sites, it marked the first major study of a targeted biologic therapy in CIDP. The trial featured a unique two-stage design: An open-label response phase followed by a randomized controlled phase for responders. Dr. Allen explains the rationale behind targeting IgG in CIDP, despite its less clear antibody-mediated mechanism compared to myasthenia gravis. The study demonstrated a 66-70% response rate in the open-label phase, with significantly lower relapse rates compared to placebo in the randomized phase. This research represents a significant advancement in CIDP treatment options, offering a weekly subcutaneous administration that could reduce treatment burden compared to traditional therapies.

Proudly Supported by

BetterHelpForvis MazarsAAOSCalendarPAmowPod

Patrons of Health Podcast Library

AAOS Now Podcast
OrthoInfo
AAOS Career Podcast
Achieving Health
Aging Like a Pro
Stronger After Stroke
Who the Health Cares? with Prof Michael Sparer

Supporting Shows

Thriving with Addiction with Dr. Jonathan Avery
Faces of Digital Health
HIT Like a Girl Pod: Empowering Women in Health IT
Speak Up For Your Health
Coffee Break: Breaking the Cycle of Bullying in Healthcare, One Cup at a Time
Hopeful Hints
Nurse Rosa's INsights
On the Pulse Podcast
This Just In Radio Show
HITea With Grace
Beyond The Paper Gown Podcast
Cuts and Consults
Impulse | Meeting Healthcare Pioneers
Coaching Healthcare Leaders
Beyond Clinical Walls
Healthcare for Humans

We use cookies to run this site. Analytics cookies, which show us how it's used, stay off unless you accept them. Change your mind any time with the cookie button at the bottom right. How we use cookies